{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:36:37Z","timestamp":1788903397033,"version":"build-2803163510"},"reference-count":54,"publisher":"Wiley","issue":"18","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,9]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n \n Fms\u2010like tyrosine kinase 3<\/jats:italic>\n (\n FLT3<\/jats:italic>\n ) mutations are associated with poor prognosis in patients with acute myeloid leukaemia (AML).\n <\/jats:p>\n <\/jats:sec>\n \n Aims<\/jats:title>\n \n We conducted a systematic literature review and meta\u2010analyses of studies reporting\n FLT3<\/jats:italic>\n mutation prevalence in patients with AML.\n <\/jats:p>\n <\/jats:sec>\n \n Materials & Methods<\/jats:title>\n We searched all publications through September 2022; the earliest publication we retrieved was published in 1997. Based on these publications, data from the studies were generated between 1985 and 2021. Prevalence was evaluated overall and by study type, geographic location of study, patient age, and gender.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Weighted mean (95% confidence interval) prevalence for\n FLT3<\/jats:italic>\n internal tandem duplication (ITD) and\n FLT3<\/jats:italic>\n tyrosine kinase domain (TKD) mutations were 20% (19%\u201322%) and 7% (6%\u20138%), respectively, with wide variability in individual study estimates (\n FLT3<\/jats:italic>\n \u2010ITD: 5.1%\u201341.4%;\n FLT3<\/jats:italic>\n \u2010TKD: 2.3%\u201312.0%). Weighted mean prevalence estimates for\n FLT3\u2010<\/jats:italic>\n ITD and\n FLT3\u2010<\/jats:italic>\n TKD mutations were higher in populations from interventional (\n FLT3\u2010<\/jats:italic>\n ITD: 22%;\n FLT3\u2010<\/jats:italic>\n TKD: 8%) than non\u2010interventional studies (\n FLT3\u2010<\/jats:italic>\n ITD: 19%;\n FLT3\u2010<\/jats:italic>\n TKD: 6%). Weighted mean\n FLT3<\/jats:italic>\n mutation prevalence estimates were higher for Europe (\n FLT3\u2010<\/jats:italic>\n ITD: 23%;\n FLT3\u2010<\/jats:italic>\n TKD: 8%) and lower for Asia (\n FLT3\u2010<\/jats:italic>\n ITD: 18%;\n FLT3\u2010<\/jats:italic>\n TKD: 5%). Weighted mean prevalence of\n FLT3<\/jats:italic>\n \u2010ITD mutations was higher in younger adults (aged 18\u201359\u2009years; 23%) than paediatric (aged <\u200918\u2009years; 12%) or older (aged \u2265\u200960\u2009years; 18%) populations, and in females (22%) than males (18%).\n <\/jats:p>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n \n This was the first study to comprehensively assess the reported prevalence of\n FLT3<\/jats:italic>\n mutations worldwide among AML patients.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n We described the distribution of\n FLT3<\/jats:italic>\n mutations; further work is needed to understand prevalence estimate heterogeneity.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/cam4.71205","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T12:37:19Z","timestamp":1758544639000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence of\n Fms\u2010Like Tyrosine Kinase 3 (FLT3)<\/i>\n Mutations in Patients With Acute Myeloid Leukaemia: A Systematic Literature Review and Meta\u2010Analysis"],"prefix":"10.1002","volume":"14","author":[{"given":"Juliana F. M.","family":"Lewis","sequence":"first","affiliation":[{"name":"Astellas Pharma, Inc. Northbrook Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2064-8925","authenticated-orcid":false,"given":"Noah Jamie","family":"Robinson","sequence":"additional","affiliation":[{"name":"Astellas Pharma A.G. Wallisellen Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4437-7457","authenticated-orcid":false,"given":"Bhavik J.","family":"Pandya","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc. Northbrook Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bosny","family":"Pierre\u2010Louis","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc. Northbrook Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayma","family":"Monir","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe B.V. Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-0356","authenticated-orcid":false,"given":"Jorge","family":"Sierra","sequence":"additional","affiliation":[{"name":"Department of Hematology Hospital Santa Creu i Sant Pau, IR\u2010Sant Pau, and Jos\u00e9 Carreras Leukemia Research Institute Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225722"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071689"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.612880"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00649-y"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-014-0579-0"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-111"},{"key":"e_1_2_10_9_1","unstructured":"S. L.West G.Gartlehner A. J.Mansfield et\u00a0al. \u201cComparative Effectiveness Review Methods: Clinical Heterogeneity \u201dRockville (MD): Agency for Healthcare Research and Quality (US); 2010 Sep. Report No.: 10\u2010EHC070\u2010EF (2010)."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-21416-0"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2006.04.004"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2164"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29395"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000331509"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2248"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-014-1595-x"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03530-9"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24135"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.5328"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.3480"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2540-7"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.6010"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.060"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.183"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03423-8"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.850163"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-740613"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1108413"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-334748"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02720-z"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1179\/1607845413Y.0000000132"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-4601-x"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000510504"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27683"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2021.10.006"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1609128"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2064-5"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3167"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-018-0616-1"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4439"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301689"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0806-0"},{"issue":"12","key":"e_1_2_10_43_1","first-page":"1911","article-title":"Internal Tandem Duplication of the flt3 Gene Found in Acute Myeloid Leukemia","volume":"10","author":"Nakao M.","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1752"},{"key":"e_1_2_10_45_1","first-page":"185","article-title":"FLT3 Mutation as a Significant Prognostic Marker in De Novo Acute Myeloid Leukemia Patients: Incidence, Distribution and Association With Cytogenetic Findings in a Study From South India","volume":"5","author":"Sarojam S.","year":"2014","journal-title":"Middle East Journal of Cancer"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_2_10_47_1","unstructured":"Margolis Center for Health Policy \u201cUnderstanding the Need for Non Interventional Studies Using Secondary Data to Generate Real\u2010World Evidence for Regulatory Decision Making and Demonstrating Their Credibility \u201d(2019) https:\/\/healthpolicy.duke.edu\/publications\/understanding\u2010need\u2010non\u2010interventional\u2010studies\u2010using\u2010secondary\u2010data\u2010generate\u2010real\u2010world. Accessed 3 September 2025."},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23397"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1329529"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3150-3"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227986"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.61"},{"key":"e_1_2_10_55_1","article-title":"Frequency of FLT3\u2010ITD and FLT3\u2010TKD Mutations in Patients With Acute Myeloid Leukemia: A Systematic Literature Review and Meta\u2010Analysis","author":"Lewis J.","year":"2021","journal-title":"European Hematology Association"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T08:29:15Z","timestamp":1766219355000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":54,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/cam4.71205"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71205","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2025-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71205"}}